About 5-hydroxytryptamine receptor 5A
5-hydroxytryptamine receptor 5A (HTR5A) is a protein
from Homo sapiens identified by UniProt accession
P47898, 357 residues long.
MolForge cross-references it against 0 known binders and
317 disease associations.
Target properties
| Protein name | 5-hydroxytryptamine receptor 5A |
| UniProt accession | P47898 |
| Gene | HTR5A |
| Organism | Homo sapiens |
| Length | 357 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (317)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.59
- schizoaffective disorder · score 0.50
- post operative nausea and vomiting · score 0.47
- depressive disorder · score 0.43
- unipolar depression · score 0.37
- psychosis · score 0.37
- mental or behavioural disorder · score 0.37
- movement disorder · score 0.37
- obesity · score 0.37
- Nausea and vomiting · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P47898-F1 | alphafold | PREDICTED | 79.64 | — |
Amino-acid sequence (357 residues)
MDLPVNLTSF SLSTPSPLET NHSLGKDDLR PSSPLLSVFG VLILTLLGFL VAATFAWNLL VLATILRVRT FHRVPHNLVA SMAVSDVLVA ALVMPLSLVH ELSGRRWQLG RRLCQLWIAC DVLCCTASIW NVTAIALDRY WSITRHMEYT LRTRKCVSNV MIALTWALSA VISLAPLLFG WGETYSEGSE ECQVSREPSY AVFSTVGAFY LPLCVVLFVY WKIYKAAKFR VGSRKTNSVS PISEAVEVKD SAKQPQMVFT VRHATVTFQP EGDTWREQKE QRAALMVGIL IGVFVLCWIP FFLTELISPL CSCDIPAIWK SIFLWLGYSN SFFNPLIYTA FNKNYNSAFK NFFSRQH
Explore 5-hydroxytryptamine receptor 5A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets